Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached
Portfolio Pulse from
Capricor Therapeutics is progressing with deramiocel, a cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Phase 2 trials showed significant improvements, but prior commercialization deals may limit upside.
December 07, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics is advancing deramiocel, a promising cell therapy for DMD-related cardiomyopathy, with potential FDA approval by 2025. Phase 2 trials showed significant improvements, but prior commercialization deals may limit upside.
Capricor's deramiocel has shown significant improvements in clinical trials, indicating potential for FDA approval by 2025. This could positively impact CAPR's stock price. However, prior commercialization deals may limit the financial upside, affecting long-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100